-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Earnings Call Summary | Applied DNA Sciences(APDN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Applied DNA Sciences(APDN.US) Q1 2024 Earnings Conference
The following is a summary of the Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript:
Financial Performance:
Applied DNA sciences reported a drop in total revenues for Q1 2024 to approximately $891,000, a decrease from the same period in the previous fiscal year due to lower clinical laboratory service revenues and product revenues.
Gross profit was $231,000, a reduction from the prior fiscal year period.
Operating expenses for Q1 2024 increased by $424,000 to $4 million in comparison to the prior fiscal year.
Operating loss increased to $3.8 million in Q1 2024, a noticeable raise from the prior fiscal period.
The company's cash equivalents went down to $3.4 million by the end of the year, compared to $7.2 million at the end of September 2023.
Business Progress:
Threatening cash position was addressed through a registered direct public offering fetching gross proceeds of approximately $3.4 million.
Their prime focus is on the commercialization of Linea IVT and Linea DNA platforms and the company is working towards leaner organization structure.
The company expects significant revenue generation from the GMP facility, which is estimated to generate about $15 million annually.
They are accelerating the commercialization of Linea IVT, providing critical starting materials for mRNA therapeutics and transitioning the manufacturing capacity to multigram scale GMP orders.
The company achieved milestones like successfully executing customers' evaluations for Linea IVT platforms and expects the GMP facility to operate by H1 calendar 2024.
In the future, they aim to establish long-term supply agreements and partner with various Contract Development and Manufacturing Organizations.
They are currently manufacturing clinical materials for trials in China and Australia and have seen rapid adoption of the Linea IVT platform since its launch in August 2023.
More details: Applied DNA Sciences IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
The following is a summary of the Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript:
以下是應用DNA科學公司(APDN)2024年第一季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Applied DNA sciences reported a drop in total revenues for Q1 2024 to approximately $891,000, a decrease from the same period in the previous fiscal year due to lower clinical laboratory service revenues and product revenues.
Gross profit was $231,000, a reduction from the prior fiscal year period.
Operating expenses for Q1 2024 increased by $424,000 to $4 million in comparison to the prior fiscal year.
Operating loss increased to $3.8 million in Q1 2024, a noticeable raise from the prior fiscal period.
The company's cash equivalents went down to $3.4 million by the end of the year, compared to $7.2 million at the end of September 2023.
應用DNA科學報告稱,由於臨床實驗室服務收入和產品收入減少,2024年第一季度的總收入下降至約89.1萬美元,較上一財年同期有所下降。
毛利爲23.1萬美元,比上一財年有所減少。
與上一財年相比,2024年第一季度的運營支出增加了42.4萬美元,達到400萬美元。
2024年第一季度的營業虧損增至380萬美元,比上一財年大幅增加。
截至年底,該公司的現金等價物降至340萬美元,而2023年9月底爲720萬美元。
Business Progress:
業務進展:
Threatening cash position was addressed through a registered direct public offering fetching gross proceeds of approximately $3.4 million.
Their prime focus is on the commercialization of Linea IVT and Linea DNA platforms and the company is working towards leaner organization structure.
The company expects significant revenue generation from the GMP facility, which is estimated to generate about $15 million annually.
They are accelerating the commercialization of Linea IVT, providing critical starting materials for mRNA therapeutics and transitioning the manufacturing capacity to multigram scale GMP orders.
The company achieved milestones like successfully executing customers' evaluations for Linea IVT platforms and expects the GMP facility to operate by H1 calendar 2024.
In the future, they aim to establish long-term supply agreements and partner with various Contract Development and Manufacturing Organizations.
They are currently manufacturing clinical materials for trials in China and Australia and have seen rapid adoption of the Linea IVT platform since its launch in August 2023.
通過註冊的直接公開募股解決了威脅性的現金狀況,總收益約爲340萬美元。
他們的主要重點是Linea IVT和Linea DNA平台的商業化,該公司正在努力實現更精簡的組織結構。
該公司預計,該GMP設施將產生可觀的收入,估計每年將產生約1500萬美元的收入。
他們正在加速Linea IVT的商業化,爲mRNA療法提供關鍵的起始材料,並將製造能力過渡到多克規模的GMP訂單。
該公司實現了里程碑,例如成功執行了客戶對Linea IVT平台的評估,並預計該GMP設施將在2024年上半年投入運營。
將來,他們的目標是建立長期供應協議,並與各種合同開發和製造組織合作。
他們目前正在爲中國和澳大利亞的試驗生產臨床材料,自2023年8月推出Linea IVT平台以來,該平台已迅速得到採用。
More details: Applied DNA Sciences IR
更多詳情: 應用 DNA 科學 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧